DCTs, Digital Therapeutics to Make Further Headway in 2024, Say Experts

Experts anticipate the new year will prove to be an impactful one for data and technology in R&D and clinical trials as companies seek to leverage big data in practical ways, simplify end-to-end data flow for sites, build single platforms for managing data and work together to drive the AI revolution forward. The following are some insights for 2024 from experts at Lokavant and Veeva Systems. Read More

Decentralized trial (DCT) methods will continue to evolve in 2024 as a group effort led by the Tufts Center for the Study of Drug Development (CSDD) to gather/utilize DCT data for informing future protocol designs aims to deliver its first dataset in the first quarter. By the end of 2024, decentralization will have established itself as the new gold standard for trials, experts predict. Read More

Steve Smith, president of patient advocacy at WCG shares insights into the controversial topic of repurposing drugs to treat new conditions. Read More

With this year’s fully virtual MAGI@home conference delivering high-energy insights and receiving a strong reception from attendees, 2024’s in-person MAGI conference in New Orleans on April 14-17 is sure to generate more of the same. The following is select coverage from the WCG Talks Trials podcast, which discussed MAGI’s success over the years. Read More

New Study Lead Opportunities from Asklepios BioPharmaceutical, Carmot Therapeutics and JCR Pharmaceuticals. Read More

New FDA Actions from Alzamend Neuro, RTI Surgical and SpringWorks Therapeutics. Read More